Proangiogenic Mechanisms and Modifications of Mesenchymal Stem Cells with a Focus on Neurological Disorders.
Zhang X., Kang H., Liu Y., Gan C., Liu Y., Ni Y.
Narrative Review, published in Stem Cells Dev (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Stem Cells Dev (2026)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41640081
- DOI
- 10.1177/15473287251413995
Abstract (original English)
Mesenchymal stem cells (MSCs) are adult stem cells with extensive differentiation potential, sourced from bone marrow, adipose tissue, umbilical cord blood, and other tissues. MSCs from different origins exhibit distinct functional characteristics. These cells have demonstrated therapeutic efficacy in various neurological disorders, primarily by modulating immune responses, promoting neovascularization, and aiding neural circuit reconstruction. Notably, the strong proangiogenic properties of MSCs play a crucial role in disease treatment and regression. This review focuses on the application of MSCs and their derivatives in neurological disorders, primarily exploring strategies to enhance their angiogenic effects, including pharmacological interventions, genetic modification, modulation of the culture environment, and the application of novel materials. Furthermore, the article prospects the potential application of MSC-mediated angiogenesis in the treatment of neurological disorders, specifically in the surgical management of ischemic cerebrovascular diseases.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.